Lorlatinib

Major

Lorlatinib Fentanyl Transdermal Patch Duragesic® Reduced CYP3A substrates exposure and reduced efficacy of CYP3A4 substrates Details Lorlatinib Finerenone Kerendia Reduced finerenone exposure and reduced efficacy of finerenone Details Lorlatinib Glasdegib Daurismo Reduced glasdegib exposure Details Lorlatinib Ibrexafungerp Brexafemme Decreased ibrexafungerp plasma concentrations Details Lorlatinib Ifosfamide Injection Ifex Increased neurotoxic and nephrotoxic effects of ifosfamide Details Lorlatinib Infigratinib Truseltiq Decreased infigratinib plasma concentrations Details Lorlatinib Ketoconazole Topical Extina® Foam Increased lorlatinib exposure and an increased risk of lorlatinib-related adverse reactions Details Lorlatinib Lefamulin Xenleta Reduced lefamulin exposure and reduced efficacy of lefamulin Details Lorlatinib Lenacapavir Injection Sunlenca Reduced lenacapavir exposure which may result in the loss of therapeutic effect and development of resistance to lenacapavir Details Lorlatinib Lenacapavir Oral Sunlenca Reduced lenacapavir exposure which may result in the loss of therapeutic effect and development of resistance to lenacapavir Details Lorlatinib Leniolisib Joenja Reduced leniolisib exposure and reduced efficacy of leniolisib Details Lorlatinib Letermovir Injection Prevymis Increased CYP3A substrates exposure, reduced letermovir exposure and reduced efficacy of letermovir Details Lorlatinib Levonorgestrel After banger Reduced levonorgestrel exposure and increased risk of breakthrough bleeding and/or contraceptive failure Details Lorlatinib Levonorgestrel Intrauterine System Kyleena Reduced levonorgestrel exposure and increased risk of breakthrough bleeding and/or contraceptive failure Details Lorlatinib Lumateperone Caplyta Reduced lumateperone exposure Details Lorlatinib Medroxyprogesterone Amen® Reduced medroxyPROGESTERone exposure Details Lorlatinib Medroxyprogesterone Injection Depo-Provera Reduced medroxyPROGESTERone exposure Details Lorlatinib Midostaurin Rydapt Reduced CYP3A substrates exposure and reduced efficacy of CYP3A4 substrates Details Lorlatinib Mitapivat Aqvesme Reduced lorlatinib exposure, reduced efficacy of lorlatinib, reduced mitapivat exposure and reduced efficacy of mitapivat Details Lorlatinib Nafcillin Injection Unipen® Injection Reduced lorlatinib exposure and reduced efficacy of lorlatinib Details Lorlatinib Neratinib Nerlynx Decreased exposure of neratinib and risk of reduced efficacy Details Lorlatinib Nifedipine Adalat® Reduced NIFEdipine exposure Details Lorlatinib Olaparib Lynparza Reduced CYP3A substrates exposure and reduced efficacy of CYP3A4 substrates Details Lorlatinib Olutasidenib Rezlidhia Reduced olutasidenib exposure Details